Paula Davila-Seijo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paula Davila-Seijo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Ignacio Garcia Doval
Dermatology Department, Complexo Hospitalario Universitario de Vigo , Vigo
8 shared publications - Angela Hernandez-Martin
Department of Dermatology Hospital Infantil Universitario Niño Jesús Madrid Spain
2 shared publications - Francisco José Gómez-García
Hospital Universitario Reina Sofía Córdoba Spain
2 shared publications - Isabel Belinchón
Department of Clinical Medicine, Miguel Hernández University, 03550 Alicante, Spain
2 shared publications - Jose Luis Lopez Estebaranz
Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
2 shared publications M.A. Descalzo
Research Unit, Fundación Piel Sana Academia Española de Dermatología y Venereología, Madrid, Spain
2 shared publications
Latest Publications
- 2 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (3) , 385
Better reporting of safety data in clinical trials of biologic drugs in psoriasis is still needed
- 2 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (3) , 385
Better reporting of safety data in clinical trials of biologic drugs in psoriasis is still needed
- 29 November 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (1) , 300-301
Registries as real‐world cohort studies that are useful and necessary in the pyramid of evidence
- 29 November 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (1) , 300-301
Registries as real‐world cohort studies that are useful and necessary in the pyramid of evidence
- 1 November 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (9) , 797
El estado de la investigación clínica en dermatología en España
- 1 November 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (9) , 797
El estado de la investigación clínica en dermatología en España
- 1 September 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (7) , 697-698
Respuesta a la réplica de Van den Reek et al. a: El análisis de supervivencia no es un buen método para evaluar la seguridad o la efectividad de los tratamientos sistémicos en psoriasis
- 1 September 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (7) , 697-698
Respuesta a la réplica de Van den Reek et al. a: El análisis de supervivencia no es un buen método para evaluar la seguridad o la efectividad de los tratamientos sistémicos en psoriasis
- Open Access
- 1 April 2017
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 97 (4) , 516-518
Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries
Is missing (Short communication)...
- 1 April 2017
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 97 (4) , 516-518
Open AccessFactors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries
Is missing (Short communication)...
- 1 February 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (2) , 313-321
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- 1 February 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (2) , 313-321
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- 1 January 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (1) , 3-5
El análisis de supervivencia no es un buen método para evaluar la seguridad o la efectividad de los tratamientos sistémicos en psoriasis
- 1 January 2017
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 108 (1) , 3-5
El análisis de supervivencia no es un buen método para evaluar la seguridad o la efectividad de los tratamientos sistémicos en psoriasis
- 22 June 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (11) , 1942-1950
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Background: Few reported studies compare drug survival in moderate‐to‐severe psoriasis vulgaris.Objectives: To describe and compare drug survival of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab and ustekinumab) and classical drugs (acitretin, ciclosporin and methotrexate) in moderate‐to‐severe psoriasis.Methods: This was a multicenter, prospective, cohort study of patients receiving systemic therapies between 2008 and 2013 in 12 hospitals in Spain. Baseline data and drug discontinuation were collected. Drug survival is presented using Kaplan–Meier survival curves. We compared adjusted risk ratios of serious adverse events (AEs) with results of survival analysis for AEs.Results: A total of 1956 patients were included for analysis (1240 exposed to biologics during follow‐up and 1076 to classic therapies). Median follow‐up time was 3.3 years (0.0–5.1 years). There were 2209 discontinuations out of 3640 therapy cycles started. The main reason for discontinuation was lack of efficacy (36.4%) and remission (27.2%). Biologics showed a higher drug survival than classics and the pattern of survival results for all outcomes (positive or negative) were very similar. Adjusted risk ratios of serious AEs did not agree with results of survival analysis.Limitations: A limitation is that this is an observational study with potential selection bias.Conclusion: Survival as a proxy measure of drug safety in psoriasis is inadequate.
- 22 June 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (11) , 1942-1950
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Background: Few reported studies compare drug survival in moderate‐to‐severe psoriasis vulgaris.Objectives: To describe and compare drug survival of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab and ustekinumab) and classical drugs (acitretin, ciclosporin and methotrexate) in moderate‐to‐severe psoriasis.Methods: This was a multicenter, prospective, cohort study of patients receiving systemic therapies between 2008 and 2013 in 12 hospitals in Spain. Baseline data and drug discontinuation were collected. Drug survival is presented using Kaplan–Meier survival curves. We compared adjusted risk ratios of serious adverse events (AEs) with results of survival analysis for AEs.Results: A total of 1956 patients were included for analysis (1240 exposed to biologics during follow‐up and 1076 to classic therapies). Median follow‐up time was 3.3 years (0.0–5.1 years). There were 2209 discontinuations out of 3640 therapy cycles started. The main reason for discontinuation was lack of efficacy (36.4%) and remission (27.2%). Biologics showed a higher drug survival than classics and the pattern of survival results for all outcomes (positive or negative) were very similar. Adjusted risk ratios of serious AEs did not agree with results of survival analysis.Limitations: A limitation is that this is an observational study with potential selection bias.Conclusion: Survival as a proxy measure of drug safety in psoriasis is inadequate.
- 1 May 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (4) , e19-e22
Síndrome LEOPARD sin sordera ni estenosis pulmonar: a propósito de 2 casos
- 1 May 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (4) , e19-e22
Síndrome LEOPARD sin sordera ni estenosis pulmonar: a propósito de 2 casos
- 1 November 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (5) , 1008-1011
Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians
- 1 November 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (5) , 1008-1011
Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians